Effects of NIDDM on very-low density lipoprotein triglyceride and apolipoprotein B metabolism

Studies before and after sulfonylurea therapy

M. R. Taskinen, W. F. Beltz, I. Harper, R. M. Fields, G. Schonfeld, Scott M Grundy, B. V. Howard

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

To evaluate mechanisms of diabetes-induced changes in very-low-density lipoprotein (VLDL), VLDL triglyceride (TG) and VLDL apoliprotein B (apoB) metabolism were studied in 12 obese Pima Indian control subjects and in 15 Pima Indian obese non-insulin-dependent diabetics. Eleven of the diabetics were restudied after reduction of hyperglycemia with oral sulfonylurea therapy. In addition, adipose, muscle, and postheparin lipoprotein lipase and postheparin hepatic lipase activities were measured in all subjects. Obese diabetics as compared with obese controls showed a trend toward increased production of VLDL TG (46 ± 4 vs. 35 ± 6 g/day, P = .10) but not of VLDL apoB (1595 ± 106 vs. 1597 ± 164 mg/day, NS); production of VLDL TG declined to control levels (33 ± 4 g/day, P < .05) during therapy, whereas there was no change in production of VLDL apoB. Diabetics had a clearance defect for VLDL, indicated by significantly lower fractional catabolic rates for both VLDL TG (10.6 ± .9 vs. 13.1 ± .9 pools/day, P < .05) and VLDL apoB (5.6 ± .4 vs. 7.5 ± 0.7, P < .05) as compared with controls; fractional catabolic rates increased after therapy (to 13.3 ± 1.5, P < .05, and 6.7 ± .4, P < .05, respectively). In the diabetics, this decrease in clearance was accompanied by a lower adipose lipoprotein lipase (.30 ± .09 vs. .92 ± .25 μmol · g-1 · h-1, P < .01), which increased during therapy (to .61 ± .17, P < .05). Hepatic lipase also decreased significantly after therapy (27.4 ± 3.6 to 26.4 ± 3.2, P < .01). Composition of VLDL in diabetics was also abnormal, indicated by a higher TG/apoB ratio (14.7 ± .6 vs. 11.7 ± .8, p < .01); this ratio fell during therapy (to 12.5 ± .8, P < .05). The data indicate there are multiple abnormalities in structure and metabolism of VLDL in non-insulin-dependent diabetics. Control of hyperglycemia with sulfonylureas has the capability of reversing some of these abnormalities.

Original languageEnglish (US)
Pages (from-to)1268-1277
Number of pages10
JournalDiabetes
Volume35
Issue number11
StatePublished - 1986

Fingerprint

VLDL Lipoproteins
Apolipoproteins B
Type 2 Diabetes Mellitus
Lipoprotein Lipase
Potassium Iodide
Therapeutics
Hyperglycemia
Multiple Abnormalities
very low density lipoprotein triglyceride
Liver
Lipase
Triglycerides
Muscles

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Taskinen, M. R., Beltz, W. F., Harper, I., Fields, R. M., Schonfeld, G., Grundy, S. M., & Howard, B. V. (1986). Effects of NIDDM on very-low density lipoprotein triglyceride and apolipoprotein B metabolism: Studies before and after sulfonylurea therapy. Diabetes, 35(11), 1268-1277.

Effects of NIDDM on very-low density lipoprotein triglyceride and apolipoprotein B metabolism : Studies before and after sulfonylurea therapy. / Taskinen, M. R.; Beltz, W. F.; Harper, I.; Fields, R. M.; Schonfeld, G.; Grundy, Scott M; Howard, B. V.

In: Diabetes, Vol. 35, No. 11, 1986, p. 1268-1277.

Research output: Contribution to journalArticle

Taskinen, MR, Beltz, WF, Harper, I, Fields, RM, Schonfeld, G, Grundy, SM & Howard, BV 1986, 'Effects of NIDDM on very-low density lipoprotein triglyceride and apolipoprotein B metabolism: Studies before and after sulfonylurea therapy', Diabetes, vol. 35, no. 11, pp. 1268-1277.
Taskinen, M. R. ; Beltz, W. F. ; Harper, I. ; Fields, R. M. ; Schonfeld, G. ; Grundy, Scott M ; Howard, B. V. / Effects of NIDDM on very-low density lipoprotein triglyceride and apolipoprotein B metabolism : Studies before and after sulfonylurea therapy. In: Diabetes. 1986 ; Vol. 35, No. 11. pp. 1268-1277.
@article{0ae68b5ea5bf413a84f5d91747ce4b88,
title = "Effects of NIDDM on very-low density lipoprotein triglyceride and apolipoprotein B metabolism: Studies before and after sulfonylurea therapy",
abstract = "To evaluate mechanisms of diabetes-induced changes in very-low-density lipoprotein (VLDL), VLDL triglyceride (TG) and VLDL apoliprotein B (apoB) metabolism were studied in 12 obese Pima Indian control subjects and in 15 Pima Indian obese non-insulin-dependent diabetics. Eleven of the diabetics were restudied after reduction of hyperglycemia with oral sulfonylurea therapy. In addition, adipose, muscle, and postheparin lipoprotein lipase and postheparin hepatic lipase activities were measured in all subjects. Obese diabetics as compared with obese controls showed a trend toward increased production of VLDL TG (46 ± 4 vs. 35 ± 6 g/day, P = .10) but not of VLDL apoB (1595 ± 106 vs. 1597 ± 164 mg/day, NS); production of VLDL TG declined to control levels (33 ± 4 g/day, P < .05) during therapy, whereas there was no change in production of VLDL apoB. Diabetics had a clearance defect for VLDL, indicated by significantly lower fractional catabolic rates for both VLDL TG (10.6 ± .9 vs. 13.1 ± .9 pools/day, P < .05) and VLDL apoB (5.6 ± .4 vs. 7.5 ± 0.7, P < .05) as compared with controls; fractional catabolic rates increased after therapy (to 13.3 ± 1.5, P < .05, and 6.7 ± .4, P < .05, respectively). In the diabetics, this decrease in clearance was accompanied by a lower adipose lipoprotein lipase (.30 ± .09 vs. .92 ± .25 μmol · g-1 · h-1, P < .01), which increased during therapy (to .61 ± .17, P < .05). Hepatic lipase also decreased significantly after therapy (27.4 ± 3.6 to 26.4 ± 3.2, P < .01). Composition of VLDL in diabetics was also abnormal, indicated by a higher TG/apoB ratio (14.7 ± .6 vs. 11.7 ± .8, p < .01); this ratio fell during therapy (to 12.5 ± .8, P < .05). The data indicate there are multiple abnormalities in structure and metabolism of VLDL in non-insulin-dependent diabetics. Control of hyperglycemia with sulfonylureas has the capability of reversing some of these abnormalities.",
author = "Taskinen, {M. R.} and Beltz, {W. F.} and I. Harper and Fields, {R. M.} and G. Schonfeld and Grundy, {Scott M} and Howard, {B. V.}",
year = "1986",
language = "English (US)",
volume = "35",
pages = "1268--1277",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "11",

}

TY - JOUR

T1 - Effects of NIDDM on very-low density lipoprotein triglyceride and apolipoprotein B metabolism

T2 - Studies before and after sulfonylurea therapy

AU - Taskinen, M. R.

AU - Beltz, W. F.

AU - Harper, I.

AU - Fields, R. M.

AU - Schonfeld, G.

AU - Grundy, Scott M

AU - Howard, B. V.

PY - 1986

Y1 - 1986

N2 - To evaluate mechanisms of diabetes-induced changes in very-low-density lipoprotein (VLDL), VLDL triglyceride (TG) and VLDL apoliprotein B (apoB) metabolism were studied in 12 obese Pima Indian control subjects and in 15 Pima Indian obese non-insulin-dependent diabetics. Eleven of the diabetics were restudied after reduction of hyperglycemia with oral sulfonylurea therapy. In addition, adipose, muscle, and postheparin lipoprotein lipase and postheparin hepatic lipase activities were measured in all subjects. Obese diabetics as compared with obese controls showed a trend toward increased production of VLDL TG (46 ± 4 vs. 35 ± 6 g/day, P = .10) but not of VLDL apoB (1595 ± 106 vs. 1597 ± 164 mg/day, NS); production of VLDL TG declined to control levels (33 ± 4 g/day, P < .05) during therapy, whereas there was no change in production of VLDL apoB. Diabetics had a clearance defect for VLDL, indicated by significantly lower fractional catabolic rates for both VLDL TG (10.6 ± .9 vs. 13.1 ± .9 pools/day, P < .05) and VLDL apoB (5.6 ± .4 vs. 7.5 ± 0.7, P < .05) as compared with controls; fractional catabolic rates increased after therapy (to 13.3 ± 1.5, P < .05, and 6.7 ± .4, P < .05, respectively). In the diabetics, this decrease in clearance was accompanied by a lower adipose lipoprotein lipase (.30 ± .09 vs. .92 ± .25 μmol · g-1 · h-1, P < .01), which increased during therapy (to .61 ± .17, P < .05). Hepatic lipase also decreased significantly after therapy (27.4 ± 3.6 to 26.4 ± 3.2, P < .01). Composition of VLDL in diabetics was also abnormal, indicated by a higher TG/apoB ratio (14.7 ± .6 vs. 11.7 ± .8, p < .01); this ratio fell during therapy (to 12.5 ± .8, P < .05). The data indicate there are multiple abnormalities in structure and metabolism of VLDL in non-insulin-dependent diabetics. Control of hyperglycemia with sulfonylureas has the capability of reversing some of these abnormalities.

AB - To evaluate mechanisms of diabetes-induced changes in very-low-density lipoprotein (VLDL), VLDL triglyceride (TG) and VLDL apoliprotein B (apoB) metabolism were studied in 12 obese Pima Indian control subjects and in 15 Pima Indian obese non-insulin-dependent diabetics. Eleven of the diabetics were restudied after reduction of hyperglycemia with oral sulfonylurea therapy. In addition, adipose, muscle, and postheparin lipoprotein lipase and postheparin hepatic lipase activities were measured in all subjects. Obese diabetics as compared with obese controls showed a trend toward increased production of VLDL TG (46 ± 4 vs. 35 ± 6 g/day, P = .10) but not of VLDL apoB (1595 ± 106 vs. 1597 ± 164 mg/day, NS); production of VLDL TG declined to control levels (33 ± 4 g/day, P < .05) during therapy, whereas there was no change in production of VLDL apoB. Diabetics had a clearance defect for VLDL, indicated by significantly lower fractional catabolic rates for both VLDL TG (10.6 ± .9 vs. 13.1 ± .9 pools/day, P < .05) and VLDL apoB (5.6 ± .4 vs. 7.5 ± 0.7, P < .05) as compared with controls; fractional catabolic rates increased after therapy (to 13.3 ± 1.5, P < .05, and 6.7 ± .4, P < .05, respectively). In the diabetics, this decrease in clearance was accompanied by a lower adipose lipoprotein lipase (.30 ± .09 vs. .92 ± .25 μmol · g-1 · h-1, P < .01), which increased during therapy (to .61 ± .17, P < .05). Hepatic lipase also decreased significantly after therapy (27.4 ± 3.6 to 26.4 ± 3.2, P < .01). Composition of VLDL in diabetics was also abnormal, indicated by a higher TG/apoB ratio (14.7 ± .6 vs. 11.7 ± .8, p < .01); this ratio fell during therapy (to 12.5 ± .8, P < .05). The data indicate there are multiple abnormalities in structure and metabolism of VLDL in non-insulin-dependent diabetics. Control of hyperglycemia with sulfonylureas has the capability of reversing some of these abnormalities.

UR - http://www.scopus.com/inward/record.url?scp=0023033051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023033051&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 1268

EP - 1277

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 11

ER -